ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on the development of products to treat and prevent serious infectious diseases, announced that it is presenting data from a Phase I clinical study of FV-100, a highly potent antiviral compound in development for the treatment of shingles, at this week’s 21st International Conference on Antiviral Research (ICAR) held April 13-17, 2008, in Montreal, Quebec. Pharmacokinetic and safety data from the study, which was conducted in the United States under an exploratory Investigational New Drug Application (IND), will be presented at a poster session later today and in an oral session tomorrow.
